NASH
MCID: NNL006
MIFTS: 54

Non-Alcoholic Steatohepatitis (NASH)

Categories: Liver diseases, Metabolic diseases, Rare diseases

Aliases & Classifications for Non-Alcoholic Steatohepatitis

MalaCards integrated aliases for Non-Alcoholic Steatohepatitis:

Name: Non-Alcoholic Steatohepatitis 12 20 15 17
Nonalcoholic Steatohepatitis 20 15 70
Nash 12 20
Non-Alcoholic Fatty Liver Disease 20

Classifications:



External Ids:

Disease Ontology 12 DOID:0080547
UMLS 70 C3241937

Summaries for Non-Alcoholic Steatohepatitis

GARD : 20 Nonalcoholic steatohepatitis, or NASH, is a common, often "silent" liver disease. It resembles alcoholic liver disease, but occurs in people who drink little or no alcohol. The major feature in NASH is fat in the liver, along with inflammation and damage. Most people with NASH feel well and are not aware that they have a liver problem. Nevertheless, NASH can be severe and can lead to cirrhosis, in which the liver is permanently damaged and scarred and no longer able to work properly. NASH most often occurs in people who are middle aged and overweight or obese. Affected individuals may also have elevated levels of blood lipids (such as cholesterol and triglycerides) and many have diabetes or prediabetes. Treatment is centered around working towards a healthy lifestyle, including weight reduction, dietary modification, increased activity and avoidance of alcohol and unnecessary medications. The underlying cause of NASH remains unclear.

MalaCards based summary : Non-Alcoholic Steatohepatitis, also known as nonalcoholic steatohepatitis, is related to non-alcoholic fatty liver disease and fatty liver disease. An important gene associated with Non-Alcoholic Steatohepatitis is MIR122 (MicroRNA 122), and among its related pathways/superpathways are Metabolism and Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha). The drugs Atorvastatin and Angiotensin II have been mentioned in the context of this disorder. Affiliated tissues include liver, endothelial and kidney, and related phenotypes are Reduced mammosphere formation and homeostasis/metabolism

Disease Ontology : 12 A nonalcoholic fatty liver disease that is characterized by the presence of inflammation with hepatocyte injury such as ballooning, with or without any fibrosis.

Related Diseases for Non-Alcoholic Steatohepatitis

Diseases related to Non-Alcoholic Steatohepatitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 807)
# Related Disease Score Top Affiliating Genes
1 non-alcoholic fatty liver disease 32.2 TNF TLR4 SIRT1 PPARG PPARA PNPLA3
2 fatty liver disease 32.0 TNF PPARG PPARA PNPLA3 MTTP MIR122
3 alcohol use disorder 31.7 HFE GPT CYP2E1 ALB
4 gestational diabetes 31.6 TNF PPARG INS IL6 ADIPOQ
5 hyperandrogenism 31.6 PPARG INS ADIPOQ
6 congestive heart failure 31.5 TNF INS IL6 ALB
7 liver disease 31.5 TNF PPARA PNPLA3 NR1H4 MTTP MIR122
8 autoimmune hepatitis 31.5 TNF KRT18 GPT ALB
9 leptin deficiency or dysfunction 31.4 TNF PPARG PPARA INS IL6 CCL2
10 hyperinsulinism 31.4 PPARG PPARA INS ADIPOQ
11 gastroesophageal reflux 31.4 TNF IL6 CCL2 ADIPOQ
12 cholelithiasis 31.4 NR1H4 INS GPT ALB
13 microvascular complications of diabetes 3 31.4 MIR21 INS ALB
14 lipid metabolism disorder 31.4 PPARG PPARA NR1H4 MTTP MIR122 INS
15 liver cirrhosis 31.4 TNF TLR4 PPARG PNPLA3 MIR122 KRT18
16 hemosiderosis 31.3 HFE GPT ALB
17 hepatitis c 31.3 TNF MIR122 KRT18 HFE GPT
18 hyperglycemia 31.3 PPARG INS IL6 ALB ADIPOQ
19 alcoholic hepatitis 31.3 TNF TLR4 PNPLA3 KRT18 IL6 GPT
20 hepatocellular carcinoma 31.3 TNF TLR4 MIR21 MIR122 KRT18 IL6
21 gout 31.2 TNF TLR4 INS IL6 ALB
22 hepatoblastoma 31.2 PPARA KRT18 IL6 CYP2E1
23 viral hepatitis 31.2 TNF TLR4 PNPLA3 MIR122 KRT18 INS
24 portal hypertension 31.2 TNF TLR4 PNPLA3 NR1H4 INS GPT
25 alpha-1-antitrypsin deficiency 31.2 TNF HFE GPT ALB
26 sleep disorder 31.1 TNF INS IL6 ALB ADIPOQ
27 cholangitis, primary sclerosing 31.1 TNF NR1H4 IL6 GPT ALB
28 placenta disease 31.1 TNF INS IL6 ADIPOQ
29 end stage renal disease 31.1 TNF INS IL6 HFE CCL2 ALB
30 diarrhea 31.1 TNF TLR4 IL6 GPT ALB
31 exanthem 31.1 TNF IL6 GPT ALB
32 pre-eclampsia 31.1 TNF TLR4 INS IL6 ALB ADIPOQ
33 glucose intolerance 31.1 TNF PPARG PPARA INS IL6 GPT
34 abdominal obesity-metabolic syndrome 1 31.0 PPARG PPARA NR1H4 MIR122 INS ADIPOQ
35 hyperuricemia 31.0 PPARG INS GPT ALB
36 stroke, ischemic 31.0 TNF TLR4 SIRT1 IL6 ALB
37 wilson disease 31.0 TNF PNPLA3 IL6 HFE GPT
38 choline deficiency disease 31.0 PPARA NR1H4 GPT
39 crohn's disease 31.0 TNF TLR4 IL6 CCL2 ALB
40 hypothyroidism 31.0 TNF INS GPT ALB ADIPOQ
41 immune deficiency disease 31.0 TNF MIR21 INS IL6 GPT CCL2
42 sclerosing cholangitis 31.0 TNF TLR4 NR1H4 IL6 GPT ALB
43 coronary heart disease 1 31.0 MTTP INS ADIPOQ
44 esophageal varix 31.0 INS GPT ALB
45 nasopharyngitis 31.0 TNF INS GPT
46 atherosclerosis susceptibility 30.9 TNF TLR4 PPARG PPARA INS IL6
47 sleep apnea 30.9 TNF INS IL6 GPT CCL2 ALB
48 skin disease 30.9 TNF PPARG PPARA MIR21 INS IL6
49 pneumonia 30.9 TNF TLR4 IL6 CCL2 ALB
50 hepatic encephalopathy 30.9 TNF IL6 GPT ALB

Graphical network of the top 20 diseases related to Non-Alcoholic Steatohepatitis:



Diseases related to Non-Alcoholic Steatohepatitis

Symptoms & Phenotypes for Non-Alcoholic Steatohepatitis

GenomeRNAi Phenotypes related to Non-Alcoholic Steatohepatitis according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.23 ACACA ALB CCL2 HFE KRT18 MTTP

MGI Mouse Phenotypes related to Non-Alcoholic Steatohepatitis:

46 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.33 ACACA ADIPOQ ALB CYP2E1 HFE IL6
2 growth/size/body region MP:0005378 10.32 ACACA ADIPOQ CYP2E1 HFE IL6 INS
3 cardiovascular system MP:0005385 10.29 ADIPOQ ALB CYP2E1 IL6 INS MTTP
4 liver/biliary system MP:0005370 10.27 ACACA ADIPOQ ALB CYP2E1 HFE IL6
5 immune system MP:0005387 10.25 ACACA ADIPOQ ALB CCL2 HFE IL6
6 adipose tissue MP:0005375 10.22 ADIPOQ IL6 INS NR1H4 PNPLA3 PPARA
7 mortality/aging MP:0010768 10.2 ACACA ADIPOQ ALB CYP2E1 HFE IL6
8 digestive/alimentary MP:0005381 10.1 ALB HFE IL6 INS NR1H4 SIRT1
9 integument MP:0010771 10.06 ADIPOQ IL6 INS NR1H4 PPARA PPARG
10 muscle MP:0005369 9.86 ADIPOQ ALB IL6 INS PPARA PPARG
11 neoplasm MP:0002006 9.81 ADIPOQ ALB CYP2E1 IL6 NR1H4 PPARG
12 renal/urinary system MP:0005367 9.56 ADIPOQ ALB IL6 INS PPARA PPARG
13 skeleton MP:0005390 9.36 ADIPOQ CYP2E1 GPT HFE IL6 INS

Drugs & Therapeutics for Non-Alcoholic Steatohepatitis

Drugs for Non-Alcoholic Steatohepatitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 370)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Atorvastatin Approved Phase 4 134523-00-5 60823
2
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 11128-99-7, 4474-91-3 172198
3
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
4
Glimepiride Approved Phase 4 93479-97-1 3476
5
Amlodipine Approved Phase 4 88150-42-9 2162
6
Perindopril Approved Phase 4 107133-36-8, 82834-16-0 107807
7
Orlistat Approved, Investigational Phase 4 96829-58-2 3034010
8
Liraglutide Approved Phase 4 204656-20-2 44147092
9
Ezetimibe Approved Phase 4 163222-33-1 150311
10
Rifampicin Approved Phase 4 13292-46-1 5381226 5458213
11
Glucagon Approved Phase 4 16941-32-5
12
Gliclazide Approved Phase 4 21187-98-4 3475
13
Insulin aspart Approved Phase 4 116094-23-6 16132418
14
Insulin detemir Approved Phase 4 169148-63-4 5311023
15
Phentermine Approved, Illicit Phase 4 122-09-8 4771
16
Ribavirin Approved Phase 4 36791-04-5 37542
17
Peginterferon alfa-2a Approved, Investigational Phase 4 198153-51-4 5360545
18
Empagliflozin Approved Phase 4 864070-44-0
19
Alogliptin Approved Phase 4 850649-61-5 11450633
20
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
21
Tocopherol Approved, Investigational Phase 4 1406-66-2
22
Dulaglutide Approved, Investigational Phase 4 923950-08-7
23
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
24
Rosiglitazone Approved, Investigational Phase 4 122320-73-4 77999
25
Metformin Approved Phase 4 657-24-9 4091 14219
26
Rifaximin Approved, Investigational Phase 4 80621-81-4 6436173 46783403
27
Zinc Approved, Investigational Phase 4 7440-66-6 32051
28
Insulin glargine Approved Phase 4 160337-95-1
29
Saxagliptin Approved Phase 4 361442-04-8 11243969
30
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 5280795 6221
31
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
32
Calcifediol Approved, Nutraceutical Phase 4 19356-17-3 5283731 6433735
33
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4 59-02-9 14985
34
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
35
Metadoxine Experimental Phase 4 74536-44-0
36
Tenofovir Experimental, Investigational Phase 4 147127-20-6 464205
37
Ipragliflozin Investigational Phase 4 761423-87-4
38 Tocotrienol Investigational Phase 4 6829-55-6
39
2,4-thiazolidinedione Investigational Phase 4 2295-31-0
40 Antihypertensive Agents Phase 4
41 Vasodilator Agents Phase 4
42 Anti-HIV Agents Phase 4
43 Giapreza Phase 4
44 Angiotensinogen Phase 4
45 Angiotensin II Type 1 Receptor Blockers Phase 4
46 Angiotensin Receptor Antagonists Phase 4
47 6-((4-ethylphenyl)methyl)-3',4',5',6'-tetrahydro-6'-(hydroxymethyl)spiro(isob... Phase 4
48 Immunosuppressive Agents Phase 4
49 Angiotensin-Converting Enzyme Inhibitors Phase 4
50 Integrase Inhibitors Phase 4

Interventional clinical trials:

(show top 50) (show all 929)
# Name Status NCT ID Phase Drugs
1 A Randomised Controlled Trial of Lifestyle Versus Ezetimibe Plus Lifestyle in Patients With Non-alcoholic Steatohepatitis Unknown status NCT01950884 Phase 4 Ezetimibe
2 THE EFFECT OF DUAL TREATMENT WITH L-CARNITINE AND MAGNESIUM ON Patients With Non Alcoholic Fatty Liver Disease Unknown status NCT01956825 Phase 4
3 Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease Unknown status NCT00941642 Phase 4 Lovaza;placebo control
4 Pleiotropic Effects and Safety of Sodium Glucose Co-transporter 2 Inhibitor Versus Sulfonylurea in Patients With Type 2 Diabetes and Non-alcoholic Fatty Liver Unknown status NCT02649465 Phase 4 Tofogliflozin;Glimepiride
5 An Randomized Open Label Trial on the Impact of 24 Weeks of Atorvastatin Therapy on Liver Fat Content and Abdominal Fat Content in Patients With Type 2 Diabetes Combined With High LDL-C and Non-alcoholic Fatty Liver Disease Unknown status NCT01720719 Phase 4 atorvastatin;Vitamin E
6 Effect of Metadoxine on Oxidative Stress in Non-alcoholic Fatty Liver Disease Prediabetic Mexican Patients Unknown status NCT02051842 Phase 4 Metadoxine
7 The Effect of Empagliflozin on NAFLD in Asian Patients With Type 2 Diabetes Unknown status NCT02964715 Phase 4 Empagliflozin
8 Pilot Study to Assess the Antiviral Activity and Safety of Besifovir Dipivoxil 150mg and L-carnitine 660mg Compared to Tenofovir Alafenamide 25mg in Chronic Hepatitis B Patients With Nonalcoholic Fatty Liver Unknown status NCT03604016 Phase 4 Besifovir dipivoxil;L-carnitine;Tenofovir Alafenamide
9 Randomized Study Comparing Switching to Raltegravir-based Antiretroviral Versus Maintaining Any Other Antiretroviral Therapy in HIV Monoinfected Patients Impact on Fatty Liver and Liver Fibrosis Assessed by Noninvasive Diagnostic Methods Unknown status NCT02210715 Phase 4 Isentress.
10 Evaluation of Perindopril and Telmisartan for the Treatment of Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial Unknown status NCT02213224 Phase 4 Perindopril;Telmisartan;Amlodipine
11 Double Blinded Randomised Trial Comparing Metformin Versus Placebo in NASH Patients Receiving Bariatric Surgery for Obesity Unknown status NCT00134303 Phase 4 Metformin
12 Orlistat (Xenical) in the Treatment of Overweight Patients With Nonalcoholic Steatohepatitis (NASH) Completed NCT00160407 Phase 4 Orlistat (Xenical)
13 Role of Pioglitazone in the Treatment of Non-alcoholic Steatohepatitis (NASH) Completed NCT00227110 Phase 4 Pioglitazone;Placebo
14 Clinical Study Evaluating the Efficacy and Safety of Montelukast in the Treatment of Non-Alcoholic Steatohepatitis (NASH) Completed NCT04537780 Phase 4 Montelukast
15 Effects of Exenatide (Byetta®) on Biochemical and Histological Parameters of Liver Function in Patients With Nonalcoholic Steatohepatitis (NASH) Completed NCT01208649 Phase 4 Exenatide
16 Long-term Role of Pioglitazone in Non-Alcoholic Fatty Liver Disease (NAFLD) in Type 2 Diabetes Mellitus (T2DM). Completed NCT00994682 Phase 4 Pioglitazone study drug;Placebo;Pioglitazone Open Label
17 NAFLD in T2DM: Prevalence in Hispanics and Role of Treatment Completed NCT01002547 Phase 4 pioglitazone-placebo;pioglitazone;pioglitazone-placebo;Vitamin E-placebo
18 PXR-aktivaation Vaikutus Maksan Rasvoittumiseen Completed NCT02329405 Phase 4 Rifampicin;Placebo
19 Comparison of Efficacy of Liraglutide, Metformin and Gliclazide MR on Hepatic Lipid Content in Patients With Type 2 Diabetes (T2DM) and Non-alcoholic Fatty Liver (NAFLD) Completed NCT03068065 Phase 4 Liraglutide;Metformin;Gliclazide
20 The Effects of Purified n-3 Fatty Acids on Serum Fibrosis Markers and Cardiovascular Risk Markers in a Randomized Placebo Controlled Trial in Patients With Non Alcoholic Fatty Liver Disease Completed NCT00760513 Phase 4 OMACOR;Placebo oral capsule
21 Use of Vitamin D in Treatment of Non-Alcoholic Fatty Liver Disease Detected by Transient Elastography Completed NCT04038853 Phase 4 1,25-Dihydroxyvitamin D;Placebo
22 Efficacy of Liraglutide vs. Sitagliptin vs. Insulin Glargine Per Day on Liver Fat When Combined With Metformin in T2DM Subjects With Non-alcoholic Fatty-liver Disease Completed NCT02147925 Phase 4 Liraglutide combined with metformin;Insulin glargine combined with metformin;Sitagliptin combined with metformin
23 Impact of Short-term Fructose-enriched Diet on Serum Metabolome by Normal- and Over-weighed Women. Completed NCT03444233 Phase 4
24 Exenatide BID Compared With Insulin Glargine to Change Liver Fat Content in Non-alcoholic Fatty-liver Disease Patients With Type 2 Diabetes Completed NCT02303730 Phase 4 Exenatide;insulin glargine
25 The Effect of Vitamin D Supplementation on the Glycemic Control and Non-alcoholic Fatty Liver Disease in Type 2 Diabetes Completed NCT01854463 Phase 4 Vitamin D3;placebo
26 A New Treatment Strategy of Adding Exenatide to Insulin Therapy for Patients With Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease (NAFLD) Completed NCT01006889 Phase 4 Exenatide
27 Effects of Ipragliflozin on Excessive Fat in Type 2 Diabetes Patients With Non-alcoholic Fatty Liver Disease Treated With Metformin and Pioglitazone Completed NCT02875821 Phase 4 Ipragliflozin;metformin with pioglitazone
28 Efficacy of Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets on the Patients With Newly Diagnosed Type 2 Diabetes Mellitus Combined With Non-alcoholic Fatty Liver Disease:an Multicenter,Randomized, Double-blind, Parallel- Controlled Study. Completed NCT03796975 Phase 4 Combination of Pioglitazone and Metformin Tablets;Metformin Hydrochloride Tablets
29 Effectiveness and Tolerability of Phentermine in the Reduction of Intrahepatic Fat Infiltration, Adipose Tissue and Postoperative Complications in Patients Under Bariatric Surgery Completed NCT03849729 Phase 4 Phentermine
30 A 24 Week, Multicenter, Prospective, Open-labeled, Single-arm, Exploratory Phase 4 Clinical Trial to Evaluate the Safety and Efficacy of Lobeglitazone in Decreasing Intrahepatic Fat Contents in Type 2 Diabetes With NAFLD Completed NCT02285205 Phase 4 Oral administration of Lobeglitazone
31 Effects of Empagliflozin on Liver Fat Content, Energy Metabolism and Body Composition in Patients With Type 2 Diabetes Completed NCT02637973 Phase 4 Empagliflozin;Placebo
32 A Randomized, Prospective, Open Label, Active Control, Phase IV Study to Evaluate the Effects of Statin Monotherapy or Statin / Ezetimibe Combination Therapy on Hepatic Steatosis in Patients With Hyperlipidemia and Nonalcoholic Fatty Liver Disease Completed NCT03434613 Phase 4 Rosuvastatin;Rosuvastatin/ezetimibe combination
33 The Comparison of Effect Between Salsalate and Placebo in Osteoarthritis With Nonalcoholic Fatty Liver Disease: Investigator Initiated Randomized Placebo-controlled Double-blind, Pilot Study Completed NCT03222206 Phase 4 Salsalate
34 A Multi-Centered, Prospective, Randomized, Placebo-Controlled Clinical Trial for the Treatment of Significant Steatosis or NASH With Xenical Followed by Treatment of Hepatitis C (HCV) With PEG-Interferon Alpha-2a/Copegus Completed NCT00207311 Phase 4 Xenical, Pegasys, Copegus
35 To Evaluate the Effect of Nesinaact on Non-alcoholic Steatohepatitis Through MRI and Liver Fibroscan in Patients With Type 2 Diabetes: A Prospective, Open-Label, Single-Arm, Single-Center Clinical Study Recruiting NCT03950505 Phase 4 Nesinaact 25/15 (Alogliptin benzoate 25mg, pioglitazone hydrochloride 15mg) treatment for 24 weeks
36 Efficacy and Safety of Berberine in Non-alcoholic Steatohepatitis: a Multicentre, Randomised, Placebo-controlled Trial Recruiting NCT03198572 Phase 4 Placebo;Berberine
37 Combined Active Treatment in Type 2 Diabetes With NASH Recruiting NCT04639414 Phase 4 Empagliflozin 10mg oral tablet / Semaglutide 1mg pen injector;Empagliflozin 10mg oral tablet and placebo pen injector matching semaglutide;Placebo matching empagliflozin and placebo pen injector matching semaglutide
38 Comparison of The Effects of Thiazolidinediones(TZD), Sodium- Glucose Cotransporter 2 Inhibitors(SGLT2i) Alone and TZD / SGLT2i Combination Therapy on Non-alcoholic Fatty Liver Disease in Type 2 Diabetic Patients With Fatty Liver Recruiting NCT03646292 Phase 4 Pioglitazone;Empagliflozin;Combination of pioglitazone and empagliflozin
39 S.P.PRO LIVER POWDER is Used to Improve Liver and Metabolic Indexes in People With Non-alcoholic Fatty Liver Disease Recruiting NCT04718051 Phase 4 Shen Pu Yang Gan Wan;Placebo
40 The Effect of Consecutive Fecal Microbiota Transplantation on Non-Alcoholic Fatty Liver Disease (NAFLD) - a Randomized-controlled Trial - Recruiting NCT04465032 Phase 4
41 A Multicenter, Double-blind, Active-controlled, Randomized, Parallel, Phase IV Clinical Trial to Evaluate the Efficacy and Safety of Evogliptin in Patients With Type 2 Diabetes and Non-alcoholic Fatty Liver Diseases Enrolling by invitation NCT03910361 Phase 4 Evogliptin;Pioglitazone
42 A Multicentre Controlled and Randomized Study Assessing the Effect of Dulaglutide add-on to Dietary Reinforcement Versus Dietary Reinforcement Alone in Patients With Type 2 Diabetes and Carriers of a Non-alcoholic Steatohepatitis Not yet recruiting NCT03648554 Phase 4 dulaglutide (TRULICITY®) 1.5 mg
43 Effect of Empagliflozin on Liver Fat in Non-alcoholic Fatty Liver Disease Patients Without Diabetes Mellitus: a Randomized, Double-blind, Placebo-controlled Trial Not yet recruiting NCT04642261 Phase 4 Empagliflozin 10 MG;Placebo pills
44 Effect of Alpha Lipoic Acid on Non-alcoholic Fatty Liver Diseases: A Randomized Placebo-controlled Clinical Trial Not yet recruiting NCT04475276 Phase 4 Placebo;Alphalipoic acid
45 Body Composition and Metabolic Manifestations of Insulin Resistance in Adolescents With Polycystic Ovary Syndrome: Ectopic Fat Deposition and Metabolic Markers: Intervention and Follow-up Portion Suspended NCT02500147 Phase 4 Metformin;Placebo
46 RiFL: Rifaximin in Fatty Liver Disease. Does Modulation of Gut Microbiota Reduce Hepatic Inflammation in Non-Alcoholic Steatohepatitis (NASH)? Terminated NCT01355575 Phase 4 Rifaximin
47 Effects of Rosiglitazone and Alpha-lipoic Acid on the Patients With Pathologically Proved NASH (Non-alcoholic Steato-hepatitis) Terminated NCT01406704 Phase 4 Rosiglitazone;alpha-lipoic acid;Rosiglitazone/alpha-lipoic acid
48 A Phase IV, Open Label, Randomized Trial on the Effect of Metformin Plus Lantus Insulin, Pioglitazone, or DPP4 Inhibitor on Fatty Liver in Patients With Type II Diabetes Terminated NCT02365233 Phase 4 DPP4 inhibitor;Pioglitazone;Lantus insulin
49 Hyperinsulinemia and Insulin Resistance in Nonalcoholic Fatty Liver Disease. Metformin for the Treatment of Nonalcoholic Fatty Liver Disease: A Randomized, Double-Blinded, Placebo-Controlled Trial Terminated NCT00736385 Phase 4 Glucophage (Metformin);Placebo
50 Natural Soybean-derived Femarelle ®for Patients With Non Alcoholic Fatty Liver Disease Withdrawn NCT01269320 Phase 4 Femarelle

Search NIH Clinical Center for Non-Alcoholic Steatohepatitis

Genetic Tests for Non-Alcoholic Steatohepatitis

Anatomical Context for Non-Alcoholic Steatohepatitis

MalaCards organs/tissues related to Non-Alcoholic Steatohepatitis:

40
Liver, Endothelial, Kidney, Ovary, T Cells, Skeletal Muscle, Neutrophil

Publications for Non-Alcoholic Steatohepatitis

Articles related to Non-Alcoholic Steatohepatitis:

(show top 50) (show all 9604)
# Title Authors PMID Year
1
Nonalcoholic fatty liver disease (NAFLD) severity is associated to a nonhemostatic contribution and proinflammatory phenotype of platelets. 61
33171266 2021
2
The role of bariatric surgery in the management of nonalcoholic steatohepatitis. 61
33769376 2021
3
Ethyl pyruvate supplemented in drinking water ameliorates experimental nonalcoholic steatohepatitis. 61
33761609 2021
4
Reciprocal association of serum Mac-2 binding protein and HDL-cholesterol concentrations. 61
33571485 2021
5
Accuracy of Two-Dimensional Shear Wave Elastography and Attenuation Imaging for Evaluation of Patients With Nonalcoholic Steatohepatitis. 61
32450363 2021
6
The Impact of Modern Chemotherapy and Chemotherapy-Associated Liver Injuries (CALI) on Liver Function: Value of 99mTc-Labelled-Mebrofenin SPECT-Hepatobiliary Scintigraphy. 61
32833150 2021
7
Prolyl endopeptidase disruption reduces hepatic inflammation and oxidative stress in methionine-choline-deficient diet-induced steatohepatitis. 61
33516698 2021
8
Crosstalk between PPARs and gut microbiota in NAFLD. 61
33485064 2021
9
The ménage à trois of autophagy, lipid droplets and liver disease. 61
33794741 2021
10
Agreement between wedged hepatic venous pressure and portal pressure in non-alcoholic steatohepatitis-related cirrhosis. 61
33068638 2021
11
Human hepatic in vitro models reveal distinct anti-NASH potencies of PPAR agonists. 61
32613381 2021
12
A large-scale internal validation study of unsupervised virtual trichrome staining technologies on nonalcoholic steatohepatitis liver biopsies. 61
33299110 2021
13
Elafibranor improves diet-induced nonalcoholic steatohepatitis associated with heart failure with preserved ejection fraction in Golden Syrian hamsters. 61
33444606 2021
14
Long non-coding RNA Meg3 deficiency impairs glucose homeostasis and insulin signaling by inducing cellular senescence of hepatic endothelium in obesity. 61
33508742 2021
15
Saroglitazar, a PPAR-α/γ Agonist, for Treatment of Nonalcoholic Fatty Liver Disease: A Randomized Controlled Double-Blind Phase 2 Trial. 61
33811367 2021
16
Non-alcoholic fatty liver disease and heart failure with preserved ejection fraction: from pathophysiology to practical issues. 61
33534958 2021
17
Pioglitazone and bariatric surgery are the most effective treatments for non-alcoholic steatohepatitis: A hierarchical network meta-analysis. 61
33368954 2021
18
Induced hepatic stellate cell integrin, α8β1, enhances cellular contractility and TGFβ activity in liver fibrosis. 61
33433924 2021
19
How Good Are Controlled Attenuation Parameter Scores from Fibroscan to Assess Steatosis, NASH, and Fibrosis? 61
32337667 2021
20
Functional Analysis of Induced Human Ballooned Hepatocytes in a Cell Sheet-Based Three Dimensional Model. 61
33517537 2021
21
The clinical impact of cirrhosis on the postoperative outcomes of patients undergoing bariatric surgery: propensity score-matched analysis of 2011-2017 US hospitals. 61
33706616 2021
22
Changing Trends in Liver Transplantation: Challenges and Solutions. 61
32910093 2021
23
Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. 61
33349658 2021
24
MR cell size imaging with temporal diffusion spectroscopy. 61
33338562 2021
25
Hydrogen-rich water protects against liver injury in nonalcoholic steatohepatitis through HO-1 enhancement via IL-10 and Sirt 1 signaling. 61
33439102 2021
26
The effect of acetylsalicylic acid and pentoxifylline in guinea pigs with non-alcoholic steatohepatitis. 61
33354924 2021
27
Osr1 regulates hepatic inflammation and cell survival in the progression of non-alcoholic fatty liver disease. 61
33005011 2021
28
Therapeutic potential of puerarin against methionine-choline-deficient diet-induced non-alcoholic steatohepatitis determined by combination of 1H NMR spectroscopy-based metabonomics and 16S rRNA gene sequencing. 61
33601157 2021
29
Long-term effects of one-anastomosis gastric bypass on liver histopathology in NAFLD cases: a prospective study. 61
32556752 2021
30
Non-alcoholic fatty liver disease: An overview of risk factors, pathophysiological mechanisms, diagnostic procedures, and therapeutic interventions. 61
33592199 2021
31
Influence of cardiometabolic comorbidities on myocardial function, infarction, and cardioprotection: Role of cardiac redox signaling. 61
33588049 2021
32
Serum aromatic and branched-chain amino acids associated with NASH demonstrate divergent associations with serum lipids. 61
33219609 2021
33
Serum levels of endotrophin are associated with nonalcoholic steatohepatitis. 61
33556256 2021
34
Exome-wide scan identifies significant association of rs4788084 in IL27 promoter with increase in hepatic fat content among Indians. 61
33444683 2021
35
Cancer Risk in Patients With Biopsy-Confirmed Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study. 61
33811766 2021
36
T-cell Dysfunction Limits Immunotherapy Efficacy in NASH-Induced Liver Cancer. 61
33811045 2021
37
Small intestinal bacterial overgrowth and non-alcoholic fatty liver disease diagnosed by transient elastography and liver biopsy. 61
33406286 2021
38
Beinaglutide shows significantly beneficial effects in diabetes/obesity-induced nonalcoholic steatohepatitis in ob/ob mouse model. 61
33482185 2021
39
NASH-related increases in plasma bile acid levels depend on insulin resistance. 61
33615207 2021
40
Quantitative, noninvasive MRI characterization of disease progression in a mouse model of non-alcoholic steatohepatitis. 61
33731798 2021
41
How histopathologic changes in pediatric nonalcoholic fatty liver disease influence in vivo liver stiffness. 61
33472102 2021
42
Characterizing disease progression of nonalcoholic steatohepatitis in Leptin-deficient rats by integrated transcriptome analysis. 61
33302736 2021
43
Decision Tree for the Performance of Intraoperative Liver Biopsy During Bariatric Surgery. 61
33665755 2021
44
Serum anandamide level as a potential indicator for nonalcoholic fatty liver disease severity. 61
33731590 2021
45
Utility of Multiparametric CT for Identification of High-Risk NAFLD. 61
33474981 2021
46
Hepatoprotective effect of Qushihuayu formula on non-alcoholic steatohepatitis induced by MCD diet in rat. 61
33726778 2021
47
Neutral sphingomyelinase-2 and cardiometabolic diseases. 61
33738905 2021
48
Beneficial effects of elafibranor on NASH in E3L.CETP mice and differences between mice and men. 61
33658534 2021
49
Neutral Ceramidase Mediates Nonalcoholic Steatohepatitis by Regulating Monounsaturated Fatty Acids and Gut IgA+ B Cells. 61
33185911 2021
50
Interleukin-2 receptor alpha as a biomarker for nonalcoholic fatty liver disease diagnosis. 61
33306598 2021

Variations for Non-Alcoholic Steatohepatitis

Expression for Non-Alcoholic Steatohepatitis

Search GEO for disease gene expression data for Non-Alcoholic Steatohepatitis.

Pathways for Non-Alcoholic Steatohepatitis

Pathways related to Non-Alcoholic Steatohepatitis according to GeneCards Suite gene sharing:

(show all 30)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.05 SIRT1 PPARG PPARA PNPLA3 NR1H4 MTTP
2
Show member pathways
12.81 TNF PPARG PPARA NR1H4 ADIPOQ ACACA
3 12.42 SIRT1 PPARG INS ADIPOQ ACACA
4
Show member pathways
12.37 SIRT1 PPARG INS ADIPOQ ACACA
5 12.15 TNF TLR4 IL6 CCL2
6
Show member pathways
12.13 TNF INS IL6 CCL2 ALB
7
Show member pathways
12.05 SIRT1 PPARG INS ADIPOQ
8 11.99 TNF TLR4 IL6 CCL2
10 11.87 TNF TLR4 IL6 CCL2
11
Show member pathways
11.82 TNF PPARA INS IL6
12 11.74 PPARG INS IL6 ADIPOQ
13
Show member pathways
11.7 TNF TLR4 IL6
14 11.7 TNF TLR4 IL6 CCL2
15 11.69 PPARG PPARA ADIPOQ
16 11.69 TNF TLR4 IL6
17 11.64 TNF PPARA ADIPOQ
18 11.61 TNF SIRT1 PPARG
19 11.61 TNF TLR4 IL6
20 11.58 TNF IL6 CCL2
21 11.53 TNF TLR4 IL6
22 11.53 SIRT1 PPARG INS ACACA
23 11.45 TNF IL6 CCL2
24 11.43 TNF TLR4 CCL2
25 11.32 TNF TLR4 IL6 CCL2
26 11.29 TNF PPARG PPARA PNPLA3 INS IL6
27 11.24 TNF TLR4 IL6
28 11.1 PPARG PPARA NR1H4 CYP2E1
29 10.69 SIRT1 PPARG
30 10.6 TNF PPARG IL6 ADIPOQ

GO Terms for Non-Alcoholic Steatohepatitis

Cellular components related to Non-Alcoholic Steatohepatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.36 TNF MIR21 MIR122 KRT18 INS IL6
2 receptor complex GO:0043235 9.26 TLR4 PPARG NR1H4 MTTP

Biological processes related to Non-Alcoholic Steatohepatitis according to GeneCards Suite gene sharing:

(show top 50) (show all 59)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.23 TNF TLR4 SIRT1 PPARG PPARA NR1H4
2 inflammatory response GO:0006954 10.07 TNF TLR4 NR1H4 IL6 CCL2
3 negative regulation of apoptotic process GO:0043066 10.07 SIRT1 NR1H4 MIR21 KRT18 IL6 ALB
4 positive regulation of apoptotic process GO:0043065 10.04 TNF SIRT1 PPARG MIR21 IL6
5 positive regulation of gene expression GO:0010628 10.04 TNF TLR4 MIR21 INS IL6 HFE
6 positive regulation of ERK1 and ERK2 cascade GO:0070374 10.01 TNF TLR4 MIR21 CCL2
7 positive regulation of protein phosphorylation GO:0001934 10 TNF SIRT1 MIR21 ADIPOQ
8 fatty acid metabolic process GO:0006631 9.98 PPARG PPARA CYP2E1 ACACA
9 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.92 TNF TLR4 INS IL6
10 negative regulation of ERK1 and ERK2 cascade GO:0070373 9.9 TLR4 MIR21 ADIPOQ
11 negative regulation of inflammatory response GO:0050728 9.9 PPARG PPARA NR1H4 ADIPOQ
12 negative regulation of tumor necrosis factor production GO:0032720 9.89 TLR4 NR1H4 ADIPOQ
13 negative regulation of interleukin-6 production GO:0032715 9.89 TNF TLR4 NR1H4
14 cellular response to starvation GO:0009267 9.89 SIRT1 PPARA ALB
15 response to glucocorticoid GO:0051384 9.88 TNF IL6 ADIPOQ
16 response to bacterium GO:0009617 9.88 TLR4 CYP2E1 CCL2 ADIPOQ
17 glucose metabolic process GO:0006006 9.87 TNF INS ADIPOQ
18 cellular response to insulin stimulus GO:0032869 9.86 PPARG PNPLA3 GPT ADIPOQ
19 humoral immune response GO:0006959 9.85 TNF IL6 CCL2
20 positive regulation of interleukin-1 beta production GO:0032731 9.84 TNF TLR4 IL6
21 positive regulation of cytokine production GO:0001819 9.84 TNF MIR21 INS
22 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.84 TNF SIRT1 MIR21 INS
23 negative regulation of I-kappaB kinase/NF-kappaB signaling GO:0043124 9.83 SIRT1 NR1H4 ADIPOQ
24 lipid homeostasis GO:0055088 9.82 PPARG PNPLA3 ACACA
25 intracellular receptor signaling pathway GO:0030522 9.79 PPARG PPARA NR1H4
26 positive regulation of chemokine production GO:0032722 9.79 TNF TLR4 IL6
27 acute-phase response GO:0006953 9.78 INS IL6 HFE
28 lipopolysaccharide-mediated signaling pathway GO:0031663 9.76 TNF TLR4 CCL2
29 positive regulation of MHC class II biosynthetic process GO:0045348 9.73 TLR4 SIRT1
30 positive regulation of chemokine (C-X-C motif) ligand 2 production GO:2000343 9.72 TNF TLR4
31 negative regulation of cholesterol storage GO:0010887 9.72 PPARG PPARA
32 positive regulation of insulin receptor signaling pathway GO:0046628 9.72 SIRT1 NR1H4 INS
33 positive regulation of peptide hormone secretion GO:0090277 9.71 INS HFE
34 negative regulation of lipid storage GO:0010888 9.71 TNF IL6
35 positive regulation of interleukin-8 production GO:0032757 9.71 TNF TLR4 IL6 ADIPOQ
36 negative regulation of receptor binding GO:1900121 9.7 HFE ADIPOQ
37 regulation of lipid storage GO:0010883 9.7 SIRT1 PPARA
38 negative regulation of acute inflammatory response GO:0002674 9.7 PPARG INS
39 negative regulation of reactive oxygen species biosynthetic process GO:1903427 9.7 PPARA MIR21 INS
40 negative regulation of interleukin-1-mediated signaling pathway GO:2000660 9.69 MIR21 IL6
41 fatty acid homeostasis GO:0055089 9.69 SIRT1 NR1H4 INS
42 cellular triglyceride homeostasis GO:0035356 9.68 SIRT1 NR1H4
43 vascular endothelial growth factor production GO:0010573 9.68 TNF IL6
44 response to sucrose GO:0009744 9.68 PNPLA3 ADIPOQ
45 positive regulation of gluconeogenesis GO:0045722 9.67 SIRT1 PPARA GPT
46 negative regulation of fat cell differentiation GO:0045599 9.67 TNF SIRT1 IL6 ADIPOQ
47 positive regulation of cAMP-dependent protein kinase activity GO:2000481 9.66 SIRT1 ADIPOQ
48 positive regulation of fatty acid oxidation GO:0046321 9.65 PPARG PPARA
49 positive regulation of leukocyte adhesion to vascular endothelial cell GO:1904996 9.65 TNF MIR21 IL6
50 glucose homeostasis GO:0042593 9.65 PPARG NR1H4 INS IL6 ADIPOQ

Molecular functions related to Non-Alcoholic Steatohepatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.56 TNF TLR4 SIRT1 PPARG INS ALB
2 cytokine activity GO:0005125 9.46 TNF IL6 CCL2 ADIPOQ
3 nuclear receptor activity GO:0004879 8.8 PPARG PPARA NR1H4

Sources for Non-Alcoholic Steatohepatitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....